H.C. Wainwright raised the firm’s price target on Aura Biosciences (AURA) to $22 from $21 and keeps a Buy rating on the shares. Due to the positive Phase 1 data for bel-sar in non-muscle invasive bladder cancer, the firm increased its probability of success to 25% from 10% in that indication.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AURA:
- Closing Bell Movers: Netflix gains 5% as Q3 earnings, Q4 guidance top estimates
- Aura Biosciences Reports Positive Phase 1 Trial Results
- Aura Biosciences announces early data from bel-sar trial
- Aura Biosciences Executives Transition and Compensation Update
- Aura Biosciences price target raised to $23 from $19 at JMP Securities